-
Of late, there has been a renaissance of interest in identification and management of hypogonadism in older men.
-
The FDA has approved the combination of dutasteride (DUT) and tamsulosin (TAM) in a single capsule. Dutasteride is a 5-a reductase inhibitor and tamsulosin is an a-adrenergic antagonist. The combination is marketed by GlaxoSmithKline as Jalyn™.
-
Use of simply obtained historical, physical, and laboratory data can distinguish gout from other forms of arthritis in many patients and avoid joint aspiration.
-
Obstructive sleep apnea is associated with an increased risk of incident heart failure in community-dwelling middle-aged and older men, but not in women.
-
In a large, well-designed observational study of patients with COPD, treatment with β-blockers during a mean follow-up period of 7.2 years was found not only to reduce the risk of exacerbations, but also to improve survival.
-
-
Fibrates: Generally safe, but do they improve outcomes? According to this meta-analysis, the answer to the question above very much depends upon which outcome you believe is important.
-
The first receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor has been approved for the treatment of osteoporosis.
-
There is no difference in rates of treatment failure, death, or readmission for COPD between patients treated with oral or intravenous steroids for exacerbation of COPD, but the IV route may be associated with increased cost and length of stay.
-
A systematic review of 9 studies showed that the COX-2 inhibitor celecoxib and ibuprofen cause less upper GI bleeding than other NSAIDs. Diclofenac, meloxicam, ketoprofen, indomethacin, and naproxen have intermediate risk. Piroxicam and ketorolac have the highest risk. In general, drugs that have a long half-life or slow-release formulation have the greatest risk of GI bleeding.